logo-loader
viewSareum Holdings PLC

Sareum’s SRA737 Chk1 inhibitor impresses once again

Sierra Oncology, the US firm which is licensing Sareum’s SRA737 compound, published more data overnight

lung x ray
SRA737 has demonstrated “clear anti-tumour activity” in pre-clinical tests

Sareum Holdings Plc (LON:SAR) shares were in demand on Friday morning after Sierra Oncology, the US firm which has licensed Sareum’s SRA737 checkpoint kinase 1 (Chk1) inhibitor candidate, published new data overnight.

Chk1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally caused by chemotherapy or radiotherapy.

In data presented at an industry conference in Miami on Thursday, SRA737 demonstrated “clear anti-tumour activity” in a preclinical model of small cell lung cancer.

READ: SRA737 could have potential in ovarian cancer

 “We are encouraged by the findings of this study, which was presented at AACR,” said Sareum chief executive Tim Mitchell.

“It showed SRA737 activated the innate immune signalling Stimulator of Interferon Genes (STING) pathway and demonstrated clear anti-tumour activity in an immunocompetent preclinical model of small cell lung cancer.

“These are important findings as SCLC remains a significant unmet need and one where immunotherapies have yielded limited efficacy. These encouraging preclinical results highlight an additional potential opportunity for SRA737 that warrants further evaluation.”

Research house Hybridan added: “This data bodes well for a potential immunotherapy combination study in humans, which if successful further augments the potential scale of future royalties to Sareum, as well as the likelihood of further success milestones.”

Shares rose 5.7% to 0.74p in early deals on Friday.

Quick facts: Sareum Holdings PLC

Price: 0.425 GBX

AIM:SAR
Market: AIM
Market Cap: £13.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: IQ-AI rockets as it receives StoneChecker FDA clearance

Headlines from the Proactive UK newsroom. IQ-AI (LON:IQAI) has received FDA clearance to market its StoneChecker Software in the US. IQ-AI said it was delighted with the decision. Synairgen (LON:SNG) is to present biomarker data from the first part of its ongoing Phase II trial of its...

on 27/9/19

2 min read